GlassScriptPhysician profile
Nathaly P Llore
NPI 1043638182
$4,017.45
in general payments reported to CMS, 2019-2025
19 companies · $1,284 in 2025
The $1,284 reported for 2025 was more than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2023: $593 · 2024: $2,033 · 2025: $1,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,259 · Travel and Lodging: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,259.31 |
| Travel and Lodging | $649.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $807.39 | 2023-2025 | |
| Histosonics, INC. | $688.82 | 2024 | |
| Intuitive Surgical, INC. | $531.71 | 2023-2025 | |
| Trisalus Life Sciences, INC. | $417.96 | 2024 | Trinav Infusion System |
| Ethicon US, LLC | $257.92 | 2023-2025 | Echelon; Endopath, Neuwave, Harmonic |
| Paragonix Technologies, INC. | $238.60 | 2025 | Liverguard |
| Organox LTD | $171.76 | 2025 | |
| Olympus America INC. | $154.46 | 2023 | Visera Elite II Video System Center Olympus Otv-S300, Olympus |
| Davol INC. | $148.99 | 2024 | Bard 3dmax Mesh |
| Integra Lifesciences Corporation | $125.46 | 2025 | Codman Certas, Cusa Clarity, Codman Hakim |
| Ipsen Biopharmaceuticals, INC | $116.67 | 2024-2025 | Bylvay |
| Allergan, INC. | $108.33 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $82.66 | 2024 | Arietta Precision |
| Mirum Pharmaceuticals, INC. | $54.71 | 2023 | Livmarli |
| Abbvie INC. | $28.14 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $21.52 | 2025 | Terlivaz |
| Boston Scientific Corporation | $21.50 | 2024 | Spyglass Discover |
| Astrazeneca Pharmaceuticals LP | $20.72 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.13 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaly Llore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.